Xenon Pharmaceuticals Inc.

Mehran Seid Bagherzadeh

Serguei Sviridov

Rajender Kamboj

Shifeng Liu

Vandna Raina

Shaoyi Sun

Zaihui Zhang

Sultan Chowdhury

Vishnumurthy Kodumuru

Duanjie Hou

Jianmin Fu

Mikhail A Chafeev

Nagasree Chakka

Robert Fraser

Melwyn A Abreo

Jianyu Sun

Michael D Winther

Heinz W Gschwend

Chi Tu

Daniel F Harvey

Wenbao Li

Mikhail Kondratenko

Cindy J Hudson

Tom Hsieh

Jian-Min Fu

Mark W Holladay

Sengen Sun

Kashinath Sadalapure

Heinz Gschwend

Michael Winther

Sun Shaoyi

Kashinath Sadalupure

Rajender K Kamboj

Mikhail Chafeev

Jian-min Fu

Mikhail A Kondratenko

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R, R, R, R, R, R, R, R, R, R, and Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase

This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain. 

Combination therapy

This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.

Spiroheterocyclic compounds and their uses as therapeutic agents

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Spiro-oxindole compounds and their uses as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein: W is &#x2014;O&#x2014;, &#x2014;N(R1)&#x2014;, C(O), S(O)t; (where t is 0, 1 or 2), N(R1)S(O)2, S(O)2N(R1), C(O)N(R1) or N(R1)C(O)N(R1); and V is C(O), C(S), C(O)N(R1)&#x2014;, C(O)O&#x2014;, S(O)2&#x2014;, S(O)2N(R1)&#x2014; or C(R11)H; and x, y, R1, R2, R3, R4, R5, R6, R7, R7, R8, R8, R9, R9, R10 and R10are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Growing community of inventors

Vancouver, Canada

Mehran Seid Bagherzadeh